EQT to acquire Oxford Biomedica plc

EQT has agreed to acquire Oxford Biomedica plc, a UK-based CDMO and viral vector specialist, in a transaction announced on 25 February 2026. The specific financial terms of the deal were not disclosed to the public, and the consideration structure remains unreported. This acquisition would have represented a significant consolidation within the biotechnology services sector, bringing the target company under the ownership of the private equity firm. The target operates from Great Britain and specialises in complex manufacturing solutions for viral vectors used in gene therapy applications.

Despite the initial agreement between the parties, the transaction has subsequently been abandoned. No completion date was ever reached, and the deal did not proceed to finalisation. The status of the proposed acquisition is now recorded as terminated, meaning Oxford Biomedica plc remains an independent entity. Regulatory approval was never sought or granted as the process ceased before reaching that stage. The parties have not provided further details regarding the specific reasons for the withdrawal of the offer.